Journal of Korean Medical Science

Korean Acad Medical Sciences (대한의학회)
권호 표지

Macrophage Activation Syndrome in a Child with Systemic Juvenile Rheumatoid Arthritis

Hur, Mi-Na;Kim, Young-Chul;Lee, Kyu-Man;Kim, Kwang-Nam

  • Published : 20050800

⟨ Previous Next ⟩

Abstract

Macrophage activation syndrome (MAS) is a rare and potentially fatal complication of rheumatic disorders in children. We describe a 13-month-old boy in whom MAS developed as a complication of systemic juvenile rheumatoid arthritis (S-JRA). He suffered from fever and generalized rash followed by multiple joints swelling for four months before admission. Physical examination revealed cervical lymphadenopathy and hepatosplenomegaly. Laboratory findings were: abnormal liver enzymes, increased triglyceride and ferritin levels, coagulopathies resembling disseminated intravascular coagulation, anemia and thrombocytopenia. Hyperplasia of hemophagocytic macrophages was remarkable in his bone marrow. Methylprednisolone and cyclosporin therapy resulted in clinical and laboratory improvements. This is the third case of MAS associated with S-JRA in Koreans, and the first one, in which hemophagocytic macrophages were proven in bone marrow.

Keywords

References

  1. Arch Dis Child v.85 Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders Sawhney, S.;Woo, P.;Murray, K.J. https://doi.org/10.1136/adc.85.5.421
  2. Rheumatology v.40 Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients Stephan, J.L.;Kone-Paut, I.;Galambrun, C.;Mouy, R.;Bader-Meunier, B.;Prieur, A.M. https://doi.org/10.1093/rheumatology/40.11.1285
  3. J Pediatr v.128 Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine Ravelli, A.;de Benedetti, F.;Viola, S.;Martini, A. https://doi.org/10.1016/S0022-3476(96)70408-0
  4. Am J Hematol v.68 Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes Emmenegger, U.;Frey, U.;Reimers, A.;Fux, C.;Semela, D.;Cottagnoud, P.;Spaeth, P.J.;Neftel, K.A. https://doi.org/10.1002/ajh.1141
  5. J Korean Pediatr Soc v.31 A case of systemic-onset juvenile rheumatoid arthritis with multiple complications Kim, J.D.;Na, D.J.;Kang, J.H.;Lee, K.S.;Sung, K.Y.
  6. J Korean Pediatr Soc v.41 A fatal case of systemic juvenile rheumatoid arthritis with disseminated intravascular coagulation Park, E.Y.;Oh, S.H.
  7. J Pediatr v.106 Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection Hadchouel, M.;Prieur, A.M.;Griscelli, C. https://doi.org/10.1016/S0022-3476(85)80072-X
  8. Baillieres Clin Rheumatol v.12 Systemic onset juvenile rheumatoid arthritis Schneider, R.;Laxer, R.M. https://doi.org/10.1016/S0950-3579(98)80018-6
  9. Clin Exp Rheumatol v.11 Macrophage activation syndrome and rheumatic diseases in childhood: A report of four new cases Stephan, J.L.;Zeller, J.;Hubert, P.;Herbelin, C;.Dayer, J.M.;Prieur, A.M.
  10. Swiss Med Wkly v.132 Reactive macrophage activation syndrome: a simple screening strategy and its potential in early treatment initiation Emmenegger, U.;Reimers, A.;Frey, U.;Fux, C.H.;Bihl, F.;Semela, D.;Cottagnoud, P.;Cerny, A.;Spaeth, P.J.;Neftel, K.A.
  11. Expert Opin Pharmacother v.2 Recent developments in the management of haemophagocytic lymphohistiocytosis Imashuku, S.;Teramura, T.;Morimoto, A.;Hibi, S. https://doi.org/10.1517/14656566.2.9.1437
  12. Br J Haematol v.87 Involvement of interferon-gamma and macrophage colony-stimulating factor in pathogenesis of haemophagocytic lymphohistiocytosis in adults Akashi, K.;Hayashi, S.;Gondo, H.;Mizuno, S.;Harada, M.;Tamura, K.;Yamasaki, K.;Shibuya, T.;Uike, N.;Okamura, T.
  13. Am J Hematol v.64 Elevation of soluble Fas and soluble Fas Ligand in reactive macrophage activation syndrome Emmenegger, U.;Zehnder, R.;Frey, U.;Reimers, A.;Spaeth, P.J.;Neftel, K.A. https://doi.org/10.1002/(SICI)1096-8652(200006)64:2<116::AID-AJH8>3.0.CO;2-8
  14. Immunol Today v.21 Perforin: more than just an effector molecule Stepp, S.E.;Mathew, P.A.;Bennett, M.;de Saint Basile, G.;Kumar, V. https://doi.org/10.1016/S0167-5699(00)01622-4
  15. Histiocytic disorders involving bone marrow;Bone marrow pathology Foucar, K.;Foucar, K.(ed.)
  16. Hematol Oncol Clin North Am v.12 Infection and malignancy associated hemophagocytic syndromes: secondary hemophagocytic lymphohistiocytosis Janka, G.;Imashuku, S.;Elinder, G.;Schneider, M.;Henter, J.I. https://doi.org/10.1016/S0889-8588(05)70521-9
  17. Med Pediatr Oncol v.29 Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society Favara, B.E.;Feller, A.C.;Pauli, M.;Jaffe, E.S.;Weiss, L.M.;Arico, M.;Bucsky, P.;Egeler, R.M.;Elinder, G.;Gadner, H.;Gresik, M.;Henter, J.I.;Imashuku, S.;Janka-Schaub, G.;Jaffe, R.;Ladisch, S.;Nezelof, C.;Pritchard, J.
  18. Clin Exp Rheumatol v.20 Is macrophage activation syndrome a new entity? Athreya, B.H.
  19. J Rheumatol v.29 Macrophage activation syndrome is hemophagocytic lymphohistiocytosis-Need for the right terminology Ramanan, A.V.;Baildam, E.M.;Wynn, R.F.
  20. J Rheumatol v.30 Macrophage activation syndrome - what’s in a name! Ramanan, A.V.;Schneider, R.